Newly Published Phase 3 SAPPHIRE Study Highlight Therapeutic Potential of Apitegromab in Spinal Muscular Atrophy
Scholar Rock’s phase 3 SAPPHIRE trial of apitegromab revealed that the treatment led to improved motor function in patients with spinal muscular atrophy over a 52-week period.